SYNLOGIC INC (SYBX) Stock Price, Quote, News and Overview
NASDAQ:SYBX - Nasdaq - US87166L2097 - Common Stock - Currency: USD
SYBX Quote, Performance and Key Statistics
NASDAQ:SYBX (2/21/2025, 8:00:01 PM)
1.36
-0.05 (-3.55%)
The current stock price of SYBX is 1.36 USD. In the past month the price decreased by -3.55%. In the past year, price decreased by -28.8%.
SYBX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SYBX
Company Profile
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Winchester, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2015-09-30. The firm is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The firm's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Company Info
SYNLOGIC INC
Po Box 30
Winchester MASSACHUSETTS 02142 US
CEO: Aoife Brennan
Employees: 6
Company Website: https://www.synlogictx.com/
Investor Relations: http://investor.mirnarx.com/index.cfm
Phone: 16176592802
SYNLOGIC INC / SYBX FAQ
What is the stock price of SYNLOGIC INC today?
The current stock price of SYBX is 1.36 USD. The price decreased by -3.55% in the last trading session.
What is the ticker symbol for SYNLOGIC INC stock?
The exchange symbol of SYNLOGIC INC is SYBX and it is listed on the Nasdaq exchange.
On which exchange is SYBX stock listed?
SYBX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SYNLOGIC INC stock?
6 analysts have analysed SYBX and the average price target is 1.02 USD. This implies a price decrease of -25% is expected in the next year compared to the current price of 1.36. Check the SYNLOGIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYNLOGIC INC worth?
SYNLOGIC INC (SYBX) has a market capitalization of 15.91M USD. This makes SYBX a Nano Cap stock.
How many employees does SYNLOGIC INC have?
SYNLOGIC INC (SYBX) currently has 6 employees.
What are the support and resistance levels for SYNLOGIC INC (SYBX) stock?
SYNLOGIC INC (SYBX) has a support level at 1.33 and a resistance level at 1.37. Check the full technical report for a detailed analysis of SYBX support and resistance levels.
Is SYNLOGIC INC (SYBX) expected to grow?
The Revenue of SYNLOGIC INC (SYBX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SYBX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SYNLOGIC INC (SYBX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SYBX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SYBX, evaluating the profitability, health, valuation and growth aspects
- SYNLOGIC INC (SYBX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYNLOGIC INC (SYBX) Sales and EPS estimates to see what analysts future expectations are.
- SYNLOGIC INC (SYBX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYNLOGIC INC (SYBX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYNLOGIC INC (SYBX) Stock Chart to make your own analysis
- SYNLOGIC INC (SYBX) Latest news and press-releases to stay up to date.
Does SYNLOGIC INC (SYBX) stock pay dividends?
SYBX does not pay a dividend.
When does SYNLOGIC INC (SYBX) report earnings?
SYNLOGIC INC (SYBX) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of SYNLOGIC INC (SYBX)?
SYNLOGIC INC (SYBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.16).
What is the Short Interest ratio of SYNLOGIC INC (SYBX) stock?
The outstanding short interest for SYNLOGIC INC (SYBX) is 0.53% of its float. Check the ownership tab for more information on the SYBX short interest.
SYBX Technical Analysis
SYBX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SYBX. While SYBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
SYBX Financial Highlights
Over the last trailing twelve months SYBX reported a non-GAAP Earnings per Share(EPS) of -4.16. The EPS increased by 67.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -331.21% | ||
| ROE | -524.44% | ||
| Debt/Equity | 0 |
SYBX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to SYBX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 74.59% and a revenue growth -100% for SYBX